PRCT
PROCEPT BioRobotics Corporation
NASDAQ · USHealthcareMedical - Devices
$19.22+0.00%
Price as of Jul 20, 2026
PRCT financials
PROCEPT BioRobotics Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M |
| Cost of revenue | $111.8M | $87.4M | $65.1M | $37.9M |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M |
| Operating expenses | $300.1M | $233.7M | $180.2M | $117.8M |
| Operating income | -$103.9M | -$96.6M | -$109.2M | -$80.7M |
| Net income | -$95.6M | -$91.4M | -$105.9M | -$87.2M |
| EBITDA | -$85.4M | -$82.0M | -$98.1M | -$79.1M |
| Basic EPS | $-1.72 | $-1.75 | $-2.24 | $-1.96 |
| Diluted EPS | $-1.72 | $-1.75 | $-2.24 | $-1.96 |
| Balance sheet | ||||
| Cash & equivalents | $286.5M | $333.7M | $257.2M | $222.6M |
| Total assets | $508.1M | $534.0M | $404.7M | $309.3M |
| Total liabilities | $142.2M | $131.8M | $124.0M | $112.3M |
| Stockholders’ equity | $365.9M | $402.2M | $280.8M | $197.1M |
| Total debt | $51.6M | $80.3M | $79.2M | $77.3M |
| Net debt | -$234.9M | -$253.5M | -$178.0M | -$145.3M |
| Cash flow | ||||
| Operating cash flow | -$49.0M | -$99.2M | -$108.0M | -$80.4M |
| Capital expenditure | -$9.4M | -$4.4M | -$25.2M | -$2.7M |
| Free cash flow | -$58.3M | -$103.6M | -$133.2M | -$83.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |